SG11202108398YA - Anti-claudin 18 antibodies and methods of use thereof - Google Patents
Anti-claudin 18 antibodies and methods of use thereofInfo
- Publication number
- SG11202108398YA SG11202108398YA SG11202108398YA SG11202108398YA SG11202108398YA SG 11202108398Y A SG11202108398Y A SG 11202108398YA SG 11202108398Y A SG11202108398Y A SG 11202108398YA SG 11202108398Y A SG11202108398Y A SG 11202108398YA SG 11202108398Y A SG11202108398Y A SG 11202108398YA
- Authority
- SG
- Singapore
- Prior art keywords
- claudin
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/828—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/852—Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800359P | 2019-02-01 | 2019-02-01 | |
| US201962891925P | 2019-08-26 | 2019-08-26 | |
| PCT/US2020/016459 WO2020160560A2 (en) | 2019-02-01 | 2020-02-03 | Anti-claudin 18 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108398YA true SG11202108398YA (en) | 2021-08-30 |
Family
ID=71842386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108398YA SG11202108398YA (en) | 2019-02-01 | 2020-02-03 | Anti-claudin 18 antibodies and methods of use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11407828B2 (en) |
| EP (1) | EP3917564A4 (en) |
| JP (1) | JP2022519118A (en) |
| KR (1) | KR20210134321A (en) |
| CN (1) | CN113645996B (en) |
| AU (1) | AU2020217012A1 (en) |
| CA (1) | CA3128502A1 (en) |
| SG (1) | SG11202108398YA (en) |
| WO (1) | WO2020160560A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11643455B2 (en) | 2018-04-13 | 2023-05-09 | Albert Einstein College Of Medicine | High-affinity Mycobacterium tuberculosis capsule-specific human monoclonal antibody |
| AU2019415848A1 (en) * | 2018-12-28 | 2021-08-19 | Nanjing GenScript Biotech Co., Ltd. | Claudin18.2 binding moieties and uses thereof |
| KR20230079096A (en) * | 2020-09-30 | 2023-06-05 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Pharmaceutical Compositions Comprising Antibody-Drug Conjugates and Uses of Pharmaceutical Compositions |
| IL303273A (en) * | 2020-11-30 | 2023-07-01 | Cspc Megalith Biopharmaceutical Co Ltd | Anti-cldn18.2 antibody, drug conjugate, and preparation method therefor and use thereof |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| US20240101650A1 (en) * | 2020-12-15 | 2024-03-28 | Albert Einstein College Of Medicine | High-Affinity Mycobacterium Tuberculosis Capsule-Specific Human Monoclonal Antibody |
| EP4267194A1 (en) | 2020-12-23 | 2023-11-01 | SOTIO Biotech a.s. | Tumor-specific claudin 18.2 antibody-drug conjugates |
| CN117642425A (en) * | 2021-05-31 | 2024-03-01 | 石家庄以岭药业股份有限公司 | Monoclonal antibodies against CLDN18.2 and Fc engineered versions thereof |
| WO2023081818A1 (en) * | 2021-11-05 | 2023-05-11 | American Diagnostics & Therapy, Llc (Adxrx) | Monoclonal antibodies against carcinoembryonic antigens, and their uses |
| CN117500529A (en) * | 2022-05-31 | 2024-02-02 | 石药集团巨石生物制药有限公司 | Pharmaceutical composition of recombinant anti-human CLDN18.2 monoclonal antibody-MMAE coupled drug |
| CN117777288A (en) * | 2022-09-29 | 2024-03-29 | 南京博望医药科技有限公司 | Antibodies against claudin 18.2 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2180007T4 (en) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosylation technique for antibodies to enhance antibody-dependent cell cytotoxicity |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| DE10254601A1 (en) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Gene products differentially expressed in tumors and their use |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| GB0306137D0 (en) | 2003-03-18 | 2003-04-23 | Qinetiq Ltd | Fibre laser |
| DE102004024617A1 (en) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentially expressed in tumors gene products and their use |
| EP2573114B1 (en) | 2005-08-10 | 2016-03-30 | MacroGenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| RS52357B (en) * | 2005-12-13 | 2012-12-31 | Medimmune Limited | Binding proteins specific for insulin-like growth factors and uses thereof |
| US20070214515A1 (en) | 2006-03-09 | 2007-09-13 | E.I.Du Pont De Nemours And Company | Polynucleotide encoding a maize herbicide resistance gene and methods for use |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| EP1997832A1 (en) * | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| EP2615115A3 (en) * | 2007-11-30 | 2014-01-08 | Glaxo Group Limited | Antigen-binding constructs |
| WO2009100324A1 (en) * | 2008-02-07 | 2009-08-13 | Schering Corporation | Engineered anti-tslpr antibodies |
| US9340603B2 (en) * | 2008-07-25 | 2016-05-17 | Institute For Research In Biomedicine | Neutralizing anti-influenza A virus antibodies and uses thereof |
| US8871207B2 (en) * | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| UA109633C2 (en) * | 2008-12-09 | 2015-09-25 | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
| WO2011086001A1 (en) | 2010-01-15 | 2011-07-21 | Cormus Srl | Antibodies for the treatment of hcv |
| WO2011107989A1 (en) | 2010-03-01 | 2011-09-09 | Lostam Biopharmaceuticals Ltd | Improved therapeutic antibodies against flagellated pseudomonas aeruginosa |
| GB201003701D0 (en) * | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
| ES2863626T3 (en) * | 2010-10-27 | 2021-10-11 | Amgen Inc | DKK1 antibodies and methods of use |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| US9371383B2 (en) | 2012-01-31 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| JO3462B1 (en) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | Human Antibodies to GFR?3 and methods of use thereof |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP2968508B1 (en) * | 2013-03-15 | 2022-04-27 | Sanofi Pasteur Biologics, LLC | Antibodies against clostridium difficile toxins and methods of using the same |
| EP3010934A4 (en) | 2013-06-17 | 2017-01-11 | The Johns Hopkins University | Antibodies to human resistin |
| SG11201702805TA (en) * | 2014-10-08 | 2017-05-30 | Hoffmann La Roche | Combination therapy of bispecific antibodies specific for fap and dr5 and chemotherapeutic agents |
| AU2015369683B2 (en) | 2014-12-23 | 2020-12-10 | Bristol-Myers Squibb Company | Antibodies to TIGIT |
| JP2018507254A (en) * | 2015-02-02 | 2018-03-15 | アイツー ファーマシューティカルズ， インコーポレーテッド | Anti-alternative light chain antibody |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| CN108348582B (en) | 2015-09-04 | 2023-04-14 | 瑞美德生物医药科技有限公司 | Methods for treating heart failure using glucagon receptor antagonist antibodies |
| PL3356413T3 (en) | 2015-10-01 | 2022-04-19 | Potenza Therapeutics, Inc. | Anti-tigit antigen-binding proteins and methods of use thereof |
| US20180282410A1 (en) | 2015-10-02 | 2018-10-04 | Hoffmann-La Roche Inc. | Anti-cd3xrob04 bispecific t cell activating antigen binding molecules |
| SG11201803817PA (en) | 2015-11-19 | 2018-06-28 | Bristol Myers Squibb Co | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| MA43658A (en) | 2016-01-22 | 2018-11-28 | Janssen Biotech Inc | ANTI-MMR1 ANTIBODIES, ROR1 X CD3 BISPECIFIC ANTIBODIES, AND METHODS OF USE THEREOF |
| CN109476751B (en) | 2016-05-27 | 2024-04-19 | 艾吉纳斯公司 | Anti-TIM-3 antibodies and methods of use thereof |
| SG11201900171QA (en) | 2016-07-08 | 2019-02-27 | Carsgen Therapeutics Co Ltd | Antibody for anti-claudin 18a2 and use thereof |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| CA3055305A1 (en) | 2017-03-22 | 2018-09-27 | Bluefin Biomedicine, Inc. | Anti-tmeff1 antibodies and antibody drug conjugates |
| SG11201909749PA (en) | 2017-04-21 | 2019-11-28 | Baylor College Medicine | Oncolytic virotherapy and immunotherapy |
| US10894833B2 (en) | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
| CA3089653A1 (en) | 2018-03-08 | 2019-09-12 | Phanes Therapeutics, Inc. | Anti-claudin 18.2 antibodies and uses thereof |
| US11485782B2 (en) | 2018-03-14 | 2022-11-01 | Beijing Xuanyi Pharmasciences Co., Ltd. | Anti-claudin 18.2 antibodies |
| SG10202111141WA (en) | 2018-05-18 | 2021-11-29 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
| US11912763B2 (en) | 2018-06-17 | 2024-02-27 | L & L Biopharma Co., Ltd. | Antibody targeting CLDN18.2, bispecific antibody, ADC, and CAR, and applications thereof |
| WO2020018852A2 (en) | 2018-07-18 | 2020-01-23 | Askgene Pharma Inc. | Novel antibodies and methods for making and using the same |
| BR112021002032A2 (en) | 2018-08-03 | 2021-07-20 | Amgen Research (Munich) Gmbh | antibody constructs for cldn18.2 and cd3 |
| CN110857322A (en) | 2018-08-22 | 2020-03-03 | 瑞阳(苏州)生物科技有限公司 | Anti-human claudin18.2 monoclonal antibody and application thereof |
| JP2021535744A (en) | 2018-08-27 | 2021-12-23 | ナンジン・サンホーム・ファーマシューティカル・カンパニー・リミテッドNanjing Sanhome Pharmaceutical Co., Ltd. | Anti-claudin 18.2 antibody and its use |
| MX2021004588A (en) | 2018-10-22 | 2022-01-18 | Shanghai Genbase Biotechnology Co Ltd | Anti-cldn128.2 antibody and uses thereof. |
| WO2020114480A1 (en) | 2018-12-07 | 2020-06-11 | Zai Lab (Shanghai) Co., Ltd. | Anti-claudin antibodies and uses thereof |
| WO2020135201A1 (en) | 2018-12-28 | 2020-07-02 | 四川科伦博泰生物医药股份有限公司 | Antibody and use thereof |
| JP2022516505A (en) | 2018-12-28 | 2022-02-28 | スパークス・セラピューティクス・インコーポレイテッド | Claudin 18.2 specific binding molecule, composition and method thereof for the treatment of cancer and other diseases. |
| CN109762067B (en) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | Antibodies that bind human Claudin18.2 and uses thereof |
| US20220184126A1 (en) | 2019-03-29 | 2022-06-16 | Phanes Therapeutis, Inc. | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof |
| BR112021019135A2 (en) | 2019-04-01 | 2021-11-30 | Jiangsu Hengrui Medicine Co | Anti-claudin antibody 18.2 and its application |
| US20220372112A1 (en) | 2019-04-19 | 2022-11-24 | Keymed Biosciences Co., Ltd. | Tumor therapeutic agent and use thereof |
| CN111944048B (en) | 2019-05-16 | 2023-10-03 | 启愈生物技术(上海)有限公司 | anti-CLDN antibody, pharmaceutical composition and detection method thereof |
| AU2020281380B2 (en) | 2019-05-30 | 2024-04-11 | Shandong Boan Biotechnology Co., Ltd. | Antibody or chimeric antigen receptor which targets claudin 18.2 |
| AU2020314119A1 (en) | 2019-07-12 | 2022-02-17 | Futuregen Biopharmaceutical (Beijing) Co., Ltd. | CLDN18.2 antibody and use thereof |
| KR20220035414A (en) | 2019-07-17 | 2022-03-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | CLAUDIN18 ANTIBODY AND CANCER TREATMENT METHOD |
| CN114630840A (en) | 2019-08-20 | 2022-06-14 | 苏州创胜医药集团有限公司 | Novel anti-CLDN 18.2 antibodies |
-
2020
- 2020-02-03 SG SG11202108398YA patent/SG11202108398YA/en unknown
- 2020-02-03 JP JP2021544859A patent/JP2022519118A/en active Pending
- 2020-02-03 AU AU2020217012A patent/AU2020217012A1/en active Pending
- 2020-02-03 KR KR1020217027503A patent/KR20210134321A/en unknown
- 2020-02-03 CA CA3128502A patent/CA3128502A1/en active Pending
- 2020-02-03 CN CN202080025850.0A patent/CN113645996B/en active Active
- 2020-02-03 US US17/427,909 patent/US11407828B2/en active Active
- 2020-02-03 WO PCT/US2020/016459 patent/WO2020160560A2/en unknown
- 2020-02-03 EP EP20748335.5A patent/EP3917564A4/en active Pending
-
2022
- 2022-06-22 US US17/846,709 patent/US20230067757A1/en active Pending
- 2022-07-13 US US17/864,335 patent/US20230272063A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3917564A4 (en) | 2022-12-21 |
| US11407828B2 (en) | 2022-08-09 |
| EP3917564A2 (en) | 2021-12-08 |
| CA3128502A1 (en) | 2020-08-06 |
| US20230067757A1 (en) | 2023-03-02 |
| US20230272063A1 (en) | 2023-08-31 |
| US20220041712A1 (en) | 2022-02-10 |
| CN113645996B (en) | 2024-04-02 |
| CN113645996A (en) | 2021-11-12 |
| KR20210134321A (en) | 2021-11-09 |
| WO2020160560A2 (en) | 2020-08-06 |
| AU2020217012A1 (en) | 2021-08-19 |
| JP2022519118A (en) | 2022-03-18 |
| WO2020160560A3 (en) | 2020-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276731A (en) | Anti-cd73 antibodies and methods of use thereof | |
| SG11202108398YA (en) | Anti-claudin 18 antibodies and methods of use thereof | |
| SG11202110145SA (en) | Antibodies against sars-cov-2 and methods of using the same | |
| SG11202010909RA (en) | Anti-msr1 antibodies and methods of use thereof | |
| IL278821A (en) | Anti-sirpa antibodies and methods of use thereof | |
| IL270214A (en) | Anti-sortilin antibodies and methods of use thereof | |
| EP3852805A4 (en) | Anti-lilrb2 antibodies and methods of use thereof | |
| IL290741A (en) | Anti-cd96 antibodies and methods of use thereof | |
| SG11202108734VA (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL287282A (en) | Anti-mertk antibodies and their methods of use | |
| IL289829A (en) | Immunomodulatory antibodies and methods of use thereof | |
| IL279648A (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
| IL289952A (en) | Anti-ms4a4a antibodies and methods of use thereof | |
| IL277212A (en) | Anti-klk5 antibodies and methods of use | |
| EP3731867A4 (en) | Anti-lrp5/6 antibodies and methods of use | |
| IL285401A (en) | Anti-clec2d antibodies and methods of use thereof | |
| IL283884A (en) | Anti-il-36 antibodies and methods of use thereof | |
| IL280338A (en) | Anti-siglec-5 antibodies and methods of use thereof | |
| IL291461A (en) | Anti-alpha-synuclein antibodies and methods of use thereof | |
| IL287039A (en) | Cd19 antibodies and methods of using the same | |
| EP3746484A4 (en) | Anti-ms4a6a antibodies and methods of use thereof | |
| EP4061848A4 (en) | Anti-ror-2 antibodies and methods of use | |
| IL279227A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
| SG11202113221RA (en) | Anti-cd137l antibodies and methods of using same | |
| IL288886A (en) | Antibodies and methods of use |